Vertex Collaborates with Ribometrix to Discover and Develop up to Three RNA Targeted Candidates

 Vertex Collaborates with Ribometrix to Discover and Develop up to Three RNA Targeted Candidates

Vertex Collaborates with Ribometrix to Discover and Develop up to Three RNA Targeted Candidates

Shots:

  • Ribometrix to get $20M up front including an equity investment in the company with $700M as development, regulatory and commercial milestones and royalties on sales on any product. Vertex to discover two programs in collaboration with Ribometrix and has an option to add the third program & to take exclusive WW license for the development and commercialization of molecules for that program
  • The collaboration will combine Ribometrix’s discovery platform with Vertex’s clinical and regulatory capabilities for up to three therapeutic programs, including one ongoing discovery program from Ribometrix
  • Ribometrix RNA-targeted therapeutics platform used for identifying and optimizing small molecule therapeutics, modulating the RNA function by targeting 3D RNA structure

Click here to­ read full press release/ article | Ref: Businesswire | Image: WBUR

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post